The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma

Jody E. Hooper, Terry Morgan, Markus Grompe, Brett Sheppard, Megan Troxell, Christopher Corless, Philip Streeter

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Metastatic pancreatic ductal adenocarcinoma and primary cholangiocarcinoma are morphologically very similar and, therefore, challenging to distinguish in liver biopsies. The distinction is important because surgical management and prognosis differ significantly. Several immunohistochemical markers have been evaluated to aid this diagnosis, but aside from N-cadherin, which labels cholangiocarcinoma, few provide the combination of good sensitivity and specificity. Our laboratory recently developed the novel monoclonal antibody human pancreatic cancer fusion #2 (HPC2) that recognizes pancreatic cancer. We hypothesized that the combination of our new marker and N-cadherin can assist in distinguishing metastatic pancreatic cancer from cholangiocarcinoma. We immunostained resections of 60 pancreatic ductal adenocarcinomas and 31 cholangiocarcinomas for the HPC2 and N-cadherin antigens. We also stained 24 gallbladder adenocarcinomas, 11 ampullary adenocarcinomas, and 10 metastatic colonic adenocarcinomas to the liver. Sections were independently scored by 2 pathologists with good agreement using both markers (κ statistics, 0.62-0.64; P

Original languageEnglish (US)
Pages (from-to)1583-1589
Number of pages7
JournalHuman Pathology
Volume43
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Cholangiocarcinoma
Cadherins
Pancreatic Neoplasms
Adenocarcinoma
Monoclonal Antibodies
Liver
Gallbladder
Biopsy
Antigens
Sensitivity and Specificity

Keywords

  • Cholangiocarcinoma
  • HPC2
  • N-cadherin
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. / Hooper, Jody E.; Morgan, Terry; Grompe, Markus; Sheppard, Brett; Troxell, Megan; Corless, Christopher; Streeter, Philip.

In: Human Pathology, Vol. 43, No. 10, 10.2012, p. 1583-1589.

Research output: Contribution to journalArticle

@article{9151bac27f61427cac71f6448cb48d45,
title = "The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma",
abstract = "Metastatic pancreatic ductal adenocarcinoma and primary cholangiocarcinoma are morphologically very similar and, therefore, challenging to distinguish in liver biopsies. The distinction is important because surgical management and prognosis differ significantly. Several immunohistochemical markers have been evaluated to aid this diagnosis, but aside from N-cadherin, which labels cholangiocarcinoma, few provide the combination of good sensitivity and specificity. Our laboratory recently developed the novel monoclonal antibody human pancreatic cancer fusion #2 (HPC2) that recognizes pancreatic cancer. We hypothesized that the combination of our new marker and N-cadherin can assist in distinguishing metastatic pancreatic cancer from cholangiocarcinoma. We immunostained resections of 60 pancreatic ductal adenocarcinomas and 31 cholangiocarcinomas for the HPC2 and N-cadherin antigens. We also stained 24 gallbladder adenocarcinomas, 11 ampullary adenocarcinomas, and 10 metastatic colonic adenocarcinomas to the liver. Sections were independently scored by 2 pathologists with good agreement using both markers (κ statistics, 0.62-0.64; P",
keywords = "Cholangiocarcinoma, HPC2, N-cadherin, Pancreatic ductal adenocarcinoma",
author = "Hooper, {Jody E.} and Terry Morgan and Markus Grompe and Brett Sheppard and Megan Troxell and Christopher Corless and Philip Streeter",
year = "2012",
month = "10",
doi = "10.1016/j.humpath.2011.11.012",
language = "English (US)",
volume = "43",
pages = "1583--1589",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma

AU - Hooper, Jody E.

AU - Morgan, Terry

AU - Grompe, Markus

AU - Sheppard, Brett

AU - Troxell, Megan

AU - Corless, Christopher

AU - Streeter, Philip

PY - 2012/10

Y1 - 2012/10

N2 - Metastatic pancreatic ductal adenocarcinoma and primary cholangiocarcinoma are morphologically very similar and, therefore, challenging to distinguish in liver biopsies. The distinction is important because surgical management and prognosis differ significantly. Several immunohistochemical markers have been evaluated to aid this diagnosis, but aside from N-cadherin, which labels cholangiocarcinoma, few provide the combination of good sensitivity and specificity. Our laboratory recently developed the novel monoclonal antibody human pancreatic cancer fusion #2 (HPC2) that recognizes pancreatic cancer. We hypothesized that the combination of our new marker and N-cadherin can assist in distinguishing metastatic pancreatic cancer from cholangiocarcinoma. We immunostained resections of 60 pancreatic ductal adenocarcinomas and 31 cholangiocarcinomas for the HPC2 and N-cadherin antigens. We also stained 24 gallbladder adenocarcinomas, 11 ampullary adenocarcinomas, and 10 metastatic colonic adenocarcinomas to the liver. Sections were independently scored by 2 pathologists with good agreement using both markers (κ statistics, 0.62-0.64; P

AB - Metastatic pancreatic ductal adenocarcinoma and primary cholangiocarcinoma are morphologically very similar and, therefore, challenging to distinguish in liver biopsies. The distinction is important because surgical management and prognosis differ significantly. Several immunohistochemical markers have been evaluated to aid this diagnosis, but aside from N-cadherin, which labels cholangiocarcinoma, few provide the combination of good sensitivity and specificity. Our laboratory recently developed the novel monoclonal antibody human pancreatic cancer fusion #2 (HPC2) that recognizes pancreatic cancer. We hypothesized that the combination of our new marker and N-cadherin can assist in distinguishing metastatic pancreatic cancer from cholangiocarcinoma. We immunostained resections of 60 pancreatic ductal adenocarcinomas and 31 cholangiocarcinomas for the HPC2 and N-cadherin antigens. We also stained 24 gallbladder adenocarcinomas, 11 ampullary adenocarcinomas, and 10 metastatic colonic adenocarcinomas to the liver. Sections were independently scored by 2 pathologists with good agreement using both markers (κ statistics, 0.62-0.64; P

KW - Cholangiocarcinoma

KW - HPC2

KW - N-cadherin

KW - Pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84866517142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866517142&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2011.11.012

DO - 10.1016/j.humpath.2011.11.012

M3 - Article

C2 - 22406361

AN - SCOPUS:84866517142

VL - 43

SP - 1583

EP - 1589

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -